{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:25:26Z","timestamp":1792218326822,"version":"4.4.0"},"reference-count":30,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2017.0481","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:29:13Z","timestamp":1525253353000},"source":"Crossref","is-referenced-by-count":18,"title":["Supportive Treatments for Patients with Cancer"],"prefix":"10.3238","author":[{"given":"Karin","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Feyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"H\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"W\u00f6rmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"10.3238\/arztebl.2017.0481_ref1","unstructured":"Robert Koch-Institut: Bericht zum Krebsgeschehen in Deutschland 2016. Zentrum f\u00fcr Krebsregisterdaten im Robert Koch-Institut (ed.) 2016."},{"key":"10.3238\/arztebl.2017.0481_ref2","doi-asserted-by":"crossref","unstructured":"Roila F, Molassiotis A, Herrstedt J, et al.: 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27: v119\u2013v33","DOI":"10.1093\/annonc\/mdw270"},{"key":"10.3238\/arztebl.2017.0481_ref3","doi-asserted-by":"crossref","unstructured":"Lalla RV, Bowen J, Barasch A, et al.: MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120: 1453\u201361","DOI":"10.1002\/cncr.28592"},{"key":"10.3238\/arztebl.2017.0481_ref4","doi-asserted-by":"crossref","unstructured":"Vehreschild JJ, Bohme A, Cornely OA, et al.: Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Ann Oncol\/ESMO 2014; 25: 1709\u201318 CrossRef","DOI":"10.1093\/annonc\/mdu035"},{"key":"10.3238\/arztebl.2017.0481_ref5","doi-asserted-by":"crossref","unstructured":"Smith TJ, Bohlke K, Lyman GH, et al.: Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2015; 33: 3199\u2013212","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"10.3238\/arztebl.2017.0481_ref6","unstructured":"Dachverband Osteologie e. V. ( DVO): Prophylaxe, Diagnostik und Therapie der Osteoporose bei M\u00e4nnern ab dem 60. Lebensjahr und postmenopausalen Frauen. Leitlinie des Dachverbandes der Deutschsprachigen wissenschaftlichen Osteologischen Gesellschaften e. V. 2014."},{"key":"10.3238\/arztebl.2017.0481_ref7","unstructured":"Deutsche Gesellschaft f\u00fcr Radioonkologie e. V. ( DEGRO): S2e-Leitlinie: Supportive Ma\u00dfnahmen in der Radioonkologie. AWMF-Register Nr 052\/014. Leitlinienprogramm Onkologie 2015. (last accessed on 22 March 2017)."},{"key":"10.3238\/arztebl.2017.0481_ref8","doi-asserted-by":"crossref","unstructured":"Ludwig H, Van Belle S, Barrett-Lee P, et al.: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer (Oxford, England: 1990): 2004; 40: 2293\u2013306","DOI":"10.1016\/j.ejca.2004.06.019"},{"key":"10.3238\/arztebl.2017.0481_ref9","doi-asserted-by":"crossref","unstructured":"Knight K, Wade S, Balducci L: Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004; 116: 11S\u201326S","DOI":"10.1016\/j.amjmed.2003.12.008"},{"key":"10.3238\/arztebl.2017.0481_ref10","doi-asserted-by":"crossref","unstructured":"Tonia T, Mettler A, Robert N, et al.: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012; 12: CD003407","DOI":"10.1002\/14651858.CD003407.pub5"},{"key":"10.3238\/arztebl.2017.0481_ref11","doi-asserted-by":"crossref","unstructured":"Machtay M, Zhang Q, Suntharalingam M, Hershock D, Lustig R, Nabid A: Long-term outcomes from RTOG 99\u201303: radiation therapy with or without erythropoietin for anemic head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2012; S21","DOI":"10.1016\/j.ijrobp.2012.07.058"},{"key":"10.3238\/arztebl.2017.0481_ref12","doi-asserted-by":"crossref","unstructured":"Moebus V, Jackisch C, Schneeweiss A, et al.: Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst 2013; 105: 1018\u201326","DOI":"10.1093\/jnci\/djt145"},{"key":"10.3238\/arztebl.2017.0481_ref13","doi-asserted-by":"crossref","unstructured":"Debus J, Drings P, Baurecht W, Angermund R: Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa. Radiother Oncol 2014; 112: 23\u20139","DOI":"10.1016\/j.radonc.2014.06.005"},{"key":"10.3238\/arztebl.2017.0481_ref14","doi-asserted-by":"crossref","unstructured":"Nitz U, Gluz O, Zuna I, et al.: Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Ann Oncol\/ESMO 2014; 25: 75\u201380","DOI":"10.1093\/annonc\/mdt505"},{"key":"10.3238\/arztebl.2017.0481_ref15","unstructured":"Hoppe JD, Scriba PC, Kl\u00fcter H: Querschnitts-Leitlinien (B\u00c4K) zur Therapie mit Blutkomponenten und Plasmaderivaten. 4. \u00fcberarbeitete und aktualisierte Auflage 2014. www.bundesaerztekammer.de\/aerzte\/medizin-ethik\/wissenschaftlicher-beirat\/veroeffentlichungen\/haemotherapie-transfusionsmedizin\/querschnitt-leitlinie (last accessed on 2 March 2016)."},{"key":"10.3238\/arztebl.2017.0481_ref16","doi-asserted-by":"crossref","unstructured":"Navari RM, Nagy CK, Gray SE: The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supp Care Cancer 2013; 21: 1655\u201363","DOI":"10.1007\/s00520-012-1710-6"},{"key":"10.3238\/arztebl.2017.0481_ref17","doi-asserted-by":"crossref","unstructured":"Osterlund P, Ruotsalainen T, Korpela R, et al.: Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 2007; 97: 1028\u201334","DOI":"10.1038\/sj.bjc.6603990"},{"key":"10.3238\/arztebl.2017.0481_ref18","doi-asserted-by":"crossref","unstructured":"Scotte F, Tourani JM, Banu E, et al.: Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005; 23: 4424\u20139","DOI":"10.1200\/JCO.2005.15.651"},{"key":"10.3238\/arztebl.2017.0481_ref19","doi-asserted-by":"crossref","unstructured":"Smith EM, Pang H, Cirrincione C, et al.: Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309: 1359\u201367","DOI":"10.1001\/jama.2013.2813"},{"key":"10.3238\/arztebl.2017.0481_ref20","doi-asserted-by":"crossref","unstructured":"Fizazi K, Lipton A, Mariette X, et al.: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564\u201371","DOI":"10.1200\/JCO.2008.19.2146"},{"key":"10.3238\/arztebl.2017.0481_ref21","doi-asserted-by":"crossref","unstructured":"Fizazi K, Carducci M, Smith M, et al.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813\u201322","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"10.3238\/arztebl.2017.0481_ref22","doi-asserted-by":"crossref","unstructured":"Henry DH, Costa L, Goldwasser F, et al.: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125\u201332","DOI":"10.1016\/j.yonc.2011.07.021"},{"key":"10.3238\/arztebl.2017.0481_ref23","doi-asserted-by":"crossref","unstructured":"Stopeck AT, Lipton A, Body JJ, et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132\u20139","DOI":"10.1200\/JCO.2010.29.7101"},{"key":"10.3238\/arztebl.2017.0481_ref24","doi-asserted-by":"crossref","unstructured":"Amadori D, Aglietta M, Alessi B, et al.: Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 2013; 14: 663\u201370","DOI":"10.1016\/S1470-2045(13)70174-8"},{"key":"10.3238\/arztebl.2017.0481_ref25","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN, Lipton A, Chew HK, et al.: Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial. J Clin Oncol 2014; 32: 5s","DOI":"10.1200\/jco.2014.32.15_suppl.lba9500"},{"key":"10.3238\/arztebl.2017.0481_ref26","doi-asserted-by":"crossref","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, et al.: Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 2017; 317: 48\u201358","DOI":"10.1001\/jama.2016.19425"},{"key":"10.3238\/arztebl.2017.0481_ref27","doi-asserted-by":"crossref","unstructured":"Gnant M, Pfeiler G, Dubsky PC, et al.: Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 433\u201343","DOI":"10.1016\/S0140-6736(15)60995-3"},{"key":"10.3238\/arztebl.2017.0481_ref28","doi-asserted-by":"crossref","unstructured":"Schmidt N, Jacob L, Coleman R, Kostev K, Hadji P: The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat 2016; 155: 151\u20137","DOI":"10.1007\/s10549-015-3661-3"},{"key":"10.3238\/arztebl.2017.0481_ref29","doi-asserted-by":"crossref","unstructured":"Mouridsen HT, Langer SW, Buter J, et al.: Treatment of anthracycline extravasation with savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol\/ESMO 2007; 18: 546\u201350","DOI":"10.1093\/annonc\/mdl413"},{"key":"10.3238\/arztebl.2017.0481_ref30","doi-asserted-by":"crossref","unstructured":"Benson AB 3rd, Ajani JA, Catalano RB, et al.: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22: 2918\u201326","DOI":"10.1200\/JCO.2004.04.132"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T10:28:40Z","timestamp":1638872920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":30,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2017.0481","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]}}}